Congenital heart defects (CHDs) have a neonatal incidence of 0.8-1% (refs. 1,2). Despite abundant examples of monogenic CHD in humans and mice, CHD has a low absolute sibling recurrence risk (~2.7%) 3 , suggesting a considerable role for de novo mutations (DNMs) and/or incomplete penetrance 4,5 . De novo proteintruncating variants (PTVs) have been shown to be enriched among the 10% of 'syndromic' patients with extra-cardiac manifestations 6,7 . We exome sequenced 1,891 probands, including both syndromic CHD (S-CHD, n = 610) and nonsyndromic CHD (NS-CHD, n = 1,281). In S-CHD, we confirmed a significant enrichment of de novo PTVs but not inherited PTVs in known CHD-associated genes, consistent with recent findings 8 . Conversely, in NS-CHD we observed significant enrichment of PTVs inherited from unaffected parents in CHD-associated genes. We identified three genome-wide significant S-CHD disorders caused by DNMs in CHD4, CDK13 and PRKD1. Our study finds evidence for distinct genetic architectures underlying the low sibling recurrence risk in S-CHD and NS-CHD.
Burden of de novo and inherited variants in NS-CHD compared to S-CHD. (a) Excess of DNMs compared to null mutation model. Excess of DNMs was computed as the ratio of the observed number of DNMs over the expected number given random mutation using a null gene-wise mutation rate model. P values were computed using a Poisson model parameterized by the cumulative mutation rate across the gene set for the same number of probands (n S-CHD = 518, n NS-CHD = 847). We stratified by variant consequence and within known autosomal dominant CHD genes (n = 78), autosomal dominant developmental-disorder-associated genes excluding autosomal dominant CHD genes (DD-non-CHD, n = 203) and all autosomal protein-coding genes excluding autosomal dominant developmental-disorder and CHD genes (n = 17, 404) . No data are shown for silent variants in CHD genes for syndromic probands, as no variants were detected. (b) Comparison of exome-wide excess of DNMs (compared to a null background mutation rate model) across different diseases stratified by variant consequence. (c) Excess of rare inherited variants (n S-CHD = 471, n NS-CHD = 663) compared to 12,031 controls of matched ancestry. Excess of DNMs was computed as the ratio of observed number of rare inherited variants to expected numbers as seen in controls. (d) Counts of de novo PTVs in S-CHD probands and rare inherited (INH) PTVs in NS-CHD probands in known monoallelic CHD-associated genes. Error bars represent 95% confidence interval.
that found in autism spectrum disorder ( Fig. 1b and Supplementary  Table 5 ). The marked difference in DNM burden between NS-CHD and S-CHD confirms findings in a recent study by Homsy et al. 8 of differences in mutational burden in CHD cases with and without neurodevelopmental deficits, which are by far the most common extra-cardiac manifestations. These differences in burden additionally mirror those observed in autism between individuals with and without intellectual disability 10 .
To evaluate the contribution of incompletely penetrant inherited variants, we compared the burden of rare (minor allele frequency (MAF) < 0.1%) inherited variants in the above described gene sets in S-CHD and NS-CHD cases of European ancestry to populationmatched controls (n = 12,031, Supplementary Fig. 1 , Supplementary  Table 6 and Fig. 1c ). We observed a significant excess of rare inherited PTVs in autosomal dominant CHD-associated genes in NS-CHD (17 variants, OR = 2.67, P = 1.1 × 10 −4 ), but not in S-CHD (P = 0.3). The CHD-associated genes with inherited PTVs in NS-CHD (Supplementary Table 7 ) have previously been linked only with nonsyndromic or syndromic presentations with variable presentations and were nonoverlapping with genes with de novo PTVs in S-CHD ( Fig. 1d) . Nonsyndromic presentations of inherited PTVs in several genes originally associated with S-CHD have been described previously (for example, JAG1 and TBX5) 11, 12 . Moreover, we observed an exome-wide excess of rare inherited PTVs (3,318 variants, OR = 1.08, P = 1.51 × 10 −5 ) in NS-CHD probands, even after excluding known CHD-associated and developmental-disorder-associated genes, suggested incomplete penetrance in additional, novel CHD-associated genes. We did not observe this exome-wide excess in the S-CHD cohort (P = 0.8), suggesting a more appreciable role for incomplete penetrance in NS-CHD than in S-CHD.
Using a previously described null mutation model 6, 9 , we evaluated individual genes for an excess of de novo PTVs and de novo missense variants separately using a high-sensitivity set of candidate DNMs and defining genome-wide significance as P < 1.3 × 10 −6 . When considering all CHD trios (S-CHD and NS-CHD), including cases with mutations in known developmental-disorder-or CHD-associated genes, we identified 11 genes with genome-wide significance. When we stratified by syndromic status, we found no genes at genomewide significance in the NS-CHD cohort. Conversely, we found the aforementioned 11 genes and one additional gene at genome-wide significance in the S-CHD cohort, in line with the increased burden of de novo PTVs in this cohort ( Table 1, Supplementary Table 8 and Fig. 2a ). Nine of the 12 genes with genome-wide significance are known to be associated with developmental disorders, although not all were previously implicated in CHD. These findings expand the known phenotypic spectrum of several genes (for example, S-CHD cases with de novo mutations in TAB2, previously described only in NS-CHD) 13 ; however, larger genotype-phenotype studies are needed to fully characterize the phenotypic spectrum associated l e t t e r s npg 1 0 6 2 VOLUME 48 | NUMBER 9 | SEPTEMBER 2016 Nature GeNetics l e t t e r s with each gene. To maximize power to detect novel causative genes, we focused on 'unresolved' S-CHD trios (i.e., probands without a plausible pathogenic DNM in known developmental-disorder-and CHD-associated genes; n = 398) and identified three genes-CDK13, CHD4 and PRKD1-at genome-wide significance ( Table 1 , Fig. 2b and Supplementary Table 9 ). All candidate DNMs in these three genes were experimentally validated. We found no genes at genomewide significance when we performed the analysis on 'unresolved' NS-CHD cases (n = 792). We identified seven S-CHD individuals ( Fig. 3a) with clustered missense variants, six de novo variants and one variant of unknown inheritance in the highly conserved serine-threonine protein kinase domain of cyclin-dependent kinase 13 (encoded by CDK13), which shows a marked depletion of missense variants in the European population ( Fig. 3b) . Four probands carry an identical missense mutation (p.Asn842Ser). These seven S-CHD cases (six trios and one singleton) were characterized by septal defects (ventral septal defects, n = 2; atrial septal defects, n = 5), with two also presenting with pulmonary valve abnormalities. Each had a recognizable facial gestalt, significant developmental delay and slight to moderate microcephaly, and two had agenesis of the corpus callosum ( Fig. 3a and Supplementary  Table 10 ). Modeling of the kinase domain indicated that the observed mutations impair ATP binding, binding of the magnesium ion that is essential for enzymatic activity or interactions with cyclin K which forms a complex with CDK13 ( Fig. 3c) . This cyclin K-CDK13 complex phosphorylates RNA polymerase II and is necessary for alternative splicing of RNA 14, 15 . Knockout mice for Cdk12-the closest paralogue of CDK13 and likewise expressed ubiquitously during development-die after implantation (embryonic day 5.5), suggesting a strong developmental effect 16 .
We observed five S-CHD individuals with DNMs in CHD4 (four missense variants and one in-frame deletion), which encodes a chromodomain-containing protein that catalyzes ATP-dependent chromatin remodeling as a core component of the nucleosome remodeling and histone deacetylase (NuRD) repressor complex 17 . Three patients manifested Tetralogy of Fallot or Fallot-like features, and the remaining two had an aortic coarctation and a septal defect, respectively ( Supplementary Fig. 2 and Supplementary Table 11 ). All had substantial early delay in neurodevelopment, two had Chiari malformations and three of the four males had cryptorchidism or ambiguous genitalia. These features suggest an overlap with CHARGE syndrome (OMIM 214800) caused by heterozygous loss-of-function mutations in the paralogous gene, CHD7, which also achieves significance in S-CHD cases ( Table 1) . Haploinsufficiency of GATAD2B, which encodes another component of the NuRD complex, has been found to cause a recognizable intellectual-disability syndrome, although associated CHD has not been reported 18 . More generally, Figure 2 Gene-wise enrichment of de novo mutations. (a,b) Gene-wise DNM enrichment for the complete S-CHD cohort (n = 518) (a) and 'unresolved' S-CHD trios without a plausible pathogenic DNM in known developmental-disorder-and CHD-associated genes (n = 398) (b). The probability of enrichment was computed given a Poisson distribution with the rate given by the gene-specific mutation rate multiplied by the number of chromosomes considered. This was performed independently for de novo PTVs and de novo missense variants. The de novo missenseenrichment probability was further combined with the probability of nonrandom clustering of de novo mutations using Fisher's method, and the minimum was taken between the combined and the original P value. The minimum probability (considering either de novo PTVs or de novo missense mutations) was plotted. The dashed horizontal line represents genome-wide significance (P < 1.31 × 10 −6 , Bonferroni-corrected P = 0.05 corrected for 2 × 19,252 protein-coding genes). npg l e t t e r s several components of other ATP-dependent chromatin-remodeling complexes have been associated with dominant developmental syndromes, including CHD in some patients 6, 7 . A recent study showed that mice with endothelial knockdown of CHD4, which results in a dysfunctional NuRD complex, die of vascular rupture during mid-gestation 19 . This finding suggests dysfunction of the NuRD complex as a possible mechanism for the observed human cardiac phenotype. We identified three S-CHD individuals with de novo missense mutations in PRKD1, with two having identical DNMs, a mutational pattern suggestive of gain of function ( Supplementary Fig. 3 and Supplementary Table 12 ). Two out of the three individuals were affected by atrioventricular septal defects, whereas the third was affected by pulmonic stenosis. Other features included severe developmental delay and ectodermal (dry skin, teeth and nail defects) and limb abnormalities. A homozygous PTV in PRKD1 has recently been associated with truncus arteriosus through autozygosity mapping 20 . PRKD1 encodes a serine-threonine kinase that regulates diverse cellular functions, including the transcriptional response to cardiac hypertrophy 21 . Homozygous knockout of Prkd1 in mice is embryonic lethal, and tissue-specific knockout results in abnormal cardiac remodeling 21 .
Counts
The burden analyses described above clearly show enrichment for de novo PTVs, de novo missense variants and inherited PTVs within our CHD data set. We therefore hypothesized that some genes might be enriched for both de novo and rare inherited variants and that integrating both classes of variation, in trios and in singletons, using a previously described hierarchical Bayesian model 22 (Online Methods) might improve power to detect novel CHD-associated genes. We analyzed PTVs and missense variants separately and considered candidate CHD-associated genes at strong (false discovery rate (FDR) < 1%), intermediate (1% < FDR < 5%) and weak (5%< FDR < 10%) levels of confidence ( Fig. 4 and Supplementary Tables 13  and 14) . We found 16 genes at the strongest level of confidence; 12 were known developmental-disorder-associated genes, one was associated with CHD but not with developmental disorders (MYH6), and three (CHD4, CDK13 and DIAPH3) were previously unknown candidate genes. Most high-confidence genes showed enrichment for either DNMs or inherited variants; only two genes, NOTCH1 and KAT6A, showed appreciable enrichment for both. NOTCH1 was notable as being the only high-confidence gene for which the evidence from inherited PTVs exceeded that from DNMs (Fig. 4b) . Owing to the likely concentration of false discovery signals in novel gene associations, this analysis alone is probably insufficient to conclusively assert novel CHD associations. Additional functional evidence can prioritize genes for future follow-up studies ( Supplementary Table 15 ). We evaluated the over-representation of particular gene functions and pathways among the top 374 genes with an FDR < 50% (Online Methods) and observed a significant (FDR < 10%) over-representation of genes associated with Gene Ontology terms relating to chromatin modification, protein phosphorylation and neural tube and cardiac development ( Supplementary Table 16 ). Over-represented pathways included NOTCH1, insulin-like growth factor-1, histone deacetylase class II, receptor tyrosine kinase ErbB and nuclear factor-κB signaling ( Supplementary Table 17 ). In addition, the 374 top-ranking genes showed considerable functional coherence, with many genes forming a single large interconnected subnetwork of high-confidence (STRING score > 0.9) protein-protein interactions ( Supplementary Fig. 4 ), the degree of interconnection of which was significantly higher than expected by chance (P = 5.84 × 10 −3 ). Key hubs in this subnetwork were NOTCH1, SOS1, EP300 and SMAD4.
Several mechanisms have been proposed to explain the low sibling recurrence risk of CHD, including a major role for DNMs 7 , incomplete penetrance of variants with large effect sizes and a polygenic and/or multifactorial etiology 23 . Our analyses (summarized in Supplementary Table 18 ) show that the relative contributions of DNMs and incomplete penetrance differ markedly between NS-CHD and S-CHD, with a major role for de novo mutations in the latter and inherited high-risk variants in the former. By focusing on unresolved S-CHD cases, we discovered three S-CHD disorders caused by mutations in genes not previously associated with S-CHD (PRKD1, CHD4 and CDK13). CHD is often not fully penetrant in S-CHD disorders (as with KMT2D and NSD1, for example) 24, 25 , and as all patients in our study were selected for CHD, further unbiased studies are necessary to quantify the penetrance of CHD in these three syndromes. These three genes increase the percentage of S-CHD probands with a putatively pathogenic DNM from 23% to 26% of patients, effectively increasing the diagnostic yield of this class of variation by 13%.
Current sample sizes provide limited statistical power to detect novel S-CHD disorders, and given the observed burden of de novo PTVs in S-CHD, we estimate that data sets at least 20-fold larger will be needed to discover most dominant CHD-associated genes (Supplementary Fig. 5 ). This challenge is likely to be even greater for identifying most genes harboring incompletely penetrant variation in NS-CHD 26 . Our data motivate different study-design strategies for S-CHD (trios) and NS-CHD (case-control), but international collaboration and data sharing will be essential to achieve a deeper understanding of the genetic architecture of CHD. 
URLs

MeTHODS
Methods and any associated references are available in the online version of the paper. npg
ONLINe MeTHODS
Cohort composition and recruitment. The CHD families analyzed in this study were recruited from multiple pediatric cardiology and clinical genetics centers from the United Kingdom, United States, Canada, Germany, Belgium and Saudi Arabia, and includes families of both European and non-European ancestry ( Supplementary Table 1 ). In addition to single-center recruitment, four multi-center cohorts were included: the DDD study, UK10K project, Competence Network for Congenital Heart Defects (Germany) and published data 7 from the Pediatric Cardiac Genetics Consortium (PCGC). The breakdown by center and study is shown in Supplementary Table 2 and by phenotype in Supplementary Table 3 . Our study focused on severely affected NS-CHD cases needing surgical intervention and S-CHD cases with clinically relevant structural heart defects. Patients were assigned to the S-CHD cohort if they showed a distinct facial gestalt or had at least one reported extra-cardiac malformation. Local institutional review boards approved all studies, and written consent was obtained from patients or parents depending on the local requirements. Within the participating institution, the phenotype status in cases was evaluated by clinical examination, two-dimensional echocardiography, magnetic resonance imaging and cardiac catheterization, surgical or physician reports and sample description provided by deposited study files. We excluded mild cardiovascular lesions, such as an existing preterm patent ductus arteriosus and patent foramen ovale, as well as isolated extra-cardiac cardiovascular lesions, such as arterial tortuosity from the analysis. Cardiac and extra-cardiac phenotypes were translated to the current European Paediatric Cardiac Code (EPCC) (version April 2015) 28 and Human Phenotype Ontology (HPO) terms 29 ( Supplementary  Table 3 ). In total, 1,365 trios, 68 probands from 32 multisibling families and 458 singleton probands were sequenced and analyzed. We also assembled a collection of 12,031 control exomes of European ancestry comprised of two data sets using similar exome-capturing platforms and applying an identical processing pipeline to that used for the CHD cohorts. The first data set incorporates 7,301 exomes (3,654 females, 3,647 males) of unaffected parents from probands that do not have CHD in the Deciphering Developmental Disorders cohort 6 . The second control data set consisted of 4,730 exomes (2,464 females, 2,266 males) of seemingly healthy blood donors as part of the INTERVAL study 30 .
The study was approved by the UK Research Ethics Committee (10/H0305/83, granted by the Cambridge South Research Ethics Committee and GEN/284/12, granted by the Republic of Ireland Research Ethics Committee), the Ethics Committee Charité Berlin, Germany (EA2/131/10), and the East Midland Research Ethics Committee (6721). Exome sequencing. Genomic DNA (approximately 1 µg) was fragmented to an average size of 150 bp and subjected to DNA library creation using established Illumina paired-end protocols. Adaptor-ligated libraries were amplified and indexed via PCR. A portion of each library was used to create an equimolar pool comprising eight indexed libraries. Each pool was hybridized to SureSelect RNA baits (Agilent Human All-Exon V3 Plus with custom ELID C0338371 and Agilent Human All-Exon V5 Plus with custom ELID C0338371), and sequence targets were captured and amplified in accordance with the manufacturer's recommendations. Enriched libraries were subjected to 75-base paired-end sequencing (Illumina HiSeq) following the manufacturer's instructions.
SNP and indel validation.
We validated all de novo variant calls reported in CDK13, CHD4 and PRKD1 using capillary sequencing. Primers were designed to amplify 400-600-bp products centered on the site of interest. Primer3 design settings were adjusted as follows, using a human mispriming library: primer length, 18 ± 3 bp, GC clamp = 1, Tm 60 ± 2. Genomic DNA from all trio members, amplified by whole-genome amplification (WGA) using illustra Genomiphi HY or V2 Amplification Kits (GE Healthcare), was used as template DNA in the site-specific PCR reactions. PCR reactions were carried out using Thermo-Start Taq DNA Polymerase (Thermo Scientific), following the manufacturer's protocol. The PCR products were assessed by agarose gel electrophoresis and submitted for sequencing to the Faculty Small Sequencing Projects (Wellcome Trust Sanger Institute core facility). Capillary sequence traces from all trio members were aligned and viewed using an in-house-designed webbased tool and scored for the presence or absence of the variant. CHD gene set curation. We curated a list of nonsyndromic and syndromic genes robustly implicated in CHD, including their inheritance mode and mechanism (for example, loss-of-function, activating). By applying consistent stringent criteria 31 (Supplementary Table 19) , we identified a total of 185 genes that have been implicated in CHD disease pathogenesis in humans up to November 2015 ( Supplementary Table 20 ). The majority of these genes are implicated in syndromic CHD (n = 152); only 31 are implicated in nonsyndromic CHD. Two genes, NOTCH1 and FLNA, have been assigned to both the syndromic and nonsyndromic disease category. 103 genes are inherited in a monoallelic (dominant) fashion, whereas 70 show a biallelic (recessive) inheritance pattern. The strongest evidence from the literature is available for tier 1 genes (n = 118) with 67 genes in the tier 2 category.
Alignment and BAM improvement. Mapping of short-read sequences for each sequencing lanelet was carried out using the Burrows-Wheeler Aligner (BWA; version 0.59) 32 backtrack algorithm with the GRCh37 1000 Genomes Project phase 2 reference (also known as hs37d5). PCR-and optically duplicated reads were marked using Picard (version 1.98) MarkDuplicates. Lanelets were spatially filtered to account for bubble artifacts and quality controlled (passing thresholds on the percentage of reads mapped; the percentage of duplicate reads marked; various statistics measuring indel distribution against read cycle; and an insert size overlap percentage). Lanelets were then merged into BAM files corresponding to the sample's libraries, and duplicates were marked again with Picard, after which the libraries were merged into BAM files for each sample. Finally, sample-level BAM improvement was carried out using the Genome Analysis Toolkit (GATK; version 3.1.1) 33 and SAMtools (version 0.1.19) 34 . This consisted of a realignment of reads around known and discovered indels followed by base quality score recalibration (BQSR), with both steps performed using GATK, and, lastly, SAMtools calmd was applied and indexes were created. The GATK3 program was made available through the generosity of Medical and Population Genetics program at the Broad Institute.
Variant calling. Known indels for realignment were taken from the Mills Devine and 1000 Genomes Project Gold set and the 1000 Genomes Project phase low-coverage set, both part of the GATK resource bundle, version 2.2. Known variants for BQSR were taken from dbSNP 137, also part of the GATK resource bundle. Finally, SNVs and indels were called using the GATK HaplotypeCaller (version 3.2.2); this was run in multisample calling mode using the complete data set. GATK variant quality score recalibration (VQSR) was then computed on the whole data set and applied to the individual-sample variant calling format (VCF) files. DeNovoGear version 0.2 (ref. 35 ) was used to detect de novo mutations (SNVs and indels) from trio exome data (BAM files) (Supplementary Tables 21-23 ). Variant calls were annotated using the Variant Effect Predictor (VEP) pipeline (Supplementary Note and Supplementary Table 24 ). Quality control and filtering at the variant and sample levels was performed at various stages of the analysis to account for technical artifacts (Supplementary Note and Supplementary Figs. 6 and 7) . Copy number variants (CNVs) were called using an in-house tool called Convex (Supplementary Note and Supplementary Tables 25 and 26) .
De novo burden analysis. We computed the excess of de novo and rare inherited variants in different sets of autosomal genes: tier 1 CHD-associated genes with a monoallelic inheritance mode (Supplementary Table 20) , developmental-disorder-associated (DD) genes with a monoallelic inheritance mode excluding CHD-associated genes and all protein-coding genes excluding monoallelic CHD and DD genes.
We compared the excess of de novo variation observed in the S-CHD and NS-CHD cohorts to a null mutation model as described in Samocha et al. 9 . The expected number of DNMs of consequence class j in a given gene set g was modeled as
l m j g i j g n , ,
with µ i,j being the gene-wise mutation rate for a given gene i and consequence class j in the gene set, and n being the number of samples in the cohort npg (with 2n being the number of observed chromosomes and n S-CHD = 518, n NS-CHD = 847). We then computed the probability of observing a DNM count equal or more extreme compared to the observed count in the S-CHD and NS-CHD cohorts through the inverse cumulative density function of this null model. The excess E of DNMs of consequence class j in a given gene set g was then computed as with DNM obs,j,g being the observed number of de novo mutations of consequence class j in gene set g in n trios of either the S-CHD or NS-CHD cohort. This number was obtained after the filtering described above, with an additional filter excluding lower-quality calls with a DeNovoGear posterior probability lower than 0.9.
Rare inherited variant burden analysis.
To compute the excess of inherited rare variants in the aforementioned gene sets, we compared the observed number of rare variants found in the CHD cases with the observed number of rare variants found in our population-matched control cohort. The expected number of variants of consequence class j in a gene set g was modeled as with c i,j being the count of rare variants found in the European control population (following the same processing pipeline and filtering protocols as the CHD cohorts), n controls being the number of controls (12,031) and n cases being the number of trios of European ancestry for the S-CHD and NS-CHD cohorts (n S-CHD = 471, n NS-CHD = 663). We then computed the probability of observing a count of rare inherited variants equal or more extreme as that observed in our CHD cohorts through the inverse cumulative density function of this null model. In addition to the aforementioned variant filters, for trios we added the prerequisite that variants in CHD cases needed to be called in the child and at least one of the parents. Also, if after filtering multiple variants were found in a single proband for a given gene, only the variant of the consequence class with the highest impact was counted (PTV > missense > silent). The excess of rare inherited variants was then computed as To exclude the possibility that the observed differences in burden of de novo and inherited variants between the S-CHD and NS-CHD cohorts might be caused by confounding variables we investigated differences between the two cohorts in variant calling, ancestry, and sex (Supplementary Note and  Supplementary Figs. 8-12 ) but found no confounding factor that could explain the observed burden of variants.
De novo burden cross-disease comparison.
We compared the genome-wide excess of de novo mutations found in our S-CHD and NS-CHD cohorts to other published studies, such as Iossifov et al. 10 for autism spectrum disorder (and unaffected siblings here denoted as controls) and non-CHD cases in the Deciphering Developmental Disorders Study 6, 36 . This was computed in the same way as described in the de novo burden analysis (but across all genes in the genome, not just autosomal genes). Owing to differences in annotation and exome-capture platforms compared to the published data sets, we used the mutation rate estimates provided in the Samocha et al. 9 study. This is in contrast to the moderately more conservative (i.e., higher) mutation rate estimates used in the burden analysis, de novo enrichment analysis and the integrated analysis of this study.
De novo enrichment analysis. Gene-specific mutation rates for different functional classes of SNVs (missense, silent, nonsense, canonical splice site, loss of stop codon) were computed using the methodology proposed by Samocha et al. 9 and as described in Fitzgerald et al. 6 . We computed the mutation rates by selecting the longest transcript in the union of transcripts overlapping the observed DNMs in that gene. This results in conservative estimates of enrichment where the (unknown) functionally active transcript can be considerably shorter than the longest overlapping transcript in Ensembl gene build 76.
We evaluated the gene-specific enrichment of PTV and missense DNMs in the S-CHD cohort by computing its statistical significance under a null hypothesis of the expected number of mutations given the gene-specific mutation rate and the number of considered chromosomes 9 . For every protein-coding gene we modeled the expected number of DNMs of consequence class j as
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Poiss( ) exp,j j ∼ l l m j j c = with µ j being the gene-and consequence-specific mutation rate and c being the number of considered chromosomes. For autosomal genes, c = 2n with n being the total number of S-CHD trios. For genes on the X chromosome c = 2n f + n m , and for genes on the Y chromosome c = n m , with n f and n m being the number of trios with female and male probands, respectively. We computed the probability under this null model of finding an equal or more extreme number of de novo mutations of consequence class j, compared to the observed number in the S-CHD cohort.
We analyzed de novo missense mutations to detect clustering of mutations within genes, indicating potential gain-of-function mechanisms. We did this by selecting the longest transcript available that contained all the source de novo variants and calculating simulated dispersions of the observed number of mutations within the gene. The probability of simulating a mutation at a specific codon was weighed by the trinucleotide sequence context 6 . For each gene, we simulated the locations of the observed number of de novo mutations 1 million times. We then computed, for the observed mutations and the simulations, the geometric mean of the distance between each pair of mutations as a metric of clustering. This allowed us to estimate the probability of the observed degree of clustering given the null model of random mutations.
Fisher's method was used to combine the significance testing of mutation enrichment and mutation clustering. This combined P value was generated only for significance testing of all missense mutations and was not used for significance testing for de novo PTVs. The assumption behind this is that genes enriched for PTVs will be operating predominantly by a mechanism of haploinsufficiency, which does not predict significant clustering of mutations, whereas genes enriched for other classes of functional mutations, predominantly missense mutations, could be operating by dominant negative or activating mechanisms, which are likely to be clustered at particular sites within the coding sequence of the gene. We then declared a gene as significantly enriched for DNMs if the minimum P value between the PTV P value and the combined missense P value was below the genome-wide significance threshold. Given the large number of tests, we assumed genome-wide significance when the probability was lower than 1.31 × 10 −6 , which represents a Bonferroni-corrected P value of 0.05 adjusted for 2 × 19,252 tests (consequence classes tested multiplied by the number of protein coding genes).
We performed the de novo enrichment analysis three times. First, we performed the analysis on the complete S-CHD cohort (as this cohort was shown to have a high burden of de novo PTVs in our previous analysis) to demonstrate the power of the approach by detecting known syndromic CHD-associated genes ( Supplementary Table 8 ). Second, we performed the analysis on the NS-CHD cohort, not detecting any genome-wide significant hits (in accordance with the lack of genome-wide burden of DNMs in nonsyndromic CHD). Third, we performed the enrichment analysis on a subset of S-CHD probands that did not carry a de novo mutation in any known monoallelic developmental-disorder-associated gene (unresolved S-CHD, n = 398). By focusing on these 'unresolved' cases with no likely diagnosis in known genes, we enrich for cases with novel causes of S-CHD, potentially increasing our power to discover novel genes ( Supplementary Table 9 ).
Integrated de novo and inherited variation analysis. To study genes that had a simultaneous enrichment of de novo mutations and rare inherited variants, we performed an integrated analysis using a hierarchical Bayesian model as described and implemented in the TADA tool by He et al. 22 . Hyperparameters were set according to TADA's guidelines (Supplementary Note, Supplementary Table 27 and Supplementary Fig. 13 ). The TADA tool ultimately outputs Bayes factors (BFs) for each source (de novo, case-control) and consequence class. These BFs represent the OR of a given gene being a CHD risk gene versus the null hypothesis of it not conferring a risk to CHD. BFs can be simply combined to generate a global score by multiplying them for each gene. On the basis of the observation that known CHD-associated genes showed signal only for PTVs or missense variants (very few genes showed moderate signal in both), we combined BFs (for de novo and case-control signal) only within each consequence class. We then computed Bayesian FDR estimates as described by He et al. 22 , then categorized candidate genes as having strong (FDR < 1%), intermediate (1%< FDR < 5%) and weak (5%< FDR < 10%) levels of confidence (Supplementary Tables 13 and 14 and Supplementary Table 28 ). We annotated these genes with mouse embryonic cardiac expression, presence of a cardiac phenotype in knockout models, the observed cardiac phenotypes in our cohort, known associated developmental disorders, known associated cardiac phenotypes and the described inheritance mode in the literature ( Supplementary Table 15 ).
Function, pathway and network analysis. In order to determine whether any gene functions or pathways were over-represented in the top-ranking genes from the TADA analysis, we used InnateDB 37 (November 2015). InnateDB's over-representation analysis performs a hypergeometric distribution test to find gene ontology terms and pathways (from KEGG, Reactome NetPath, INOH, BioCarta and PID) that are represented more than would be expected by chance given a set of genes. As an input set we used all genes with an FDR < 50% (n = 374 or the top 2% quantile of protein-coding genes) from the de novo and inherited variant integrated TADA analysis. Owing to the large number of terms and pathways tested, we considered a term or pathway to be over-represented if the Benjamini-Hochberg-corrected FDR was less than 10% (Supplementary Tables 16 and 17) .
Additionally, we looked for an over-representation of protein-protein interactions (PPIs) within this set of top-ranking genes using the STRING (version 10) PPI database 38 . To avoid potentially spurious low-confidence interactions, we restricted our analysis to interactions with a confidence score of 0.9 or higher. STRING allows the possibility to compute the probability of finding an equal or higher number of PPIs given a random set of genes. In our case, the top-ranking genes showed a significant enrichment of within-set high confidence interactions (P = 5.84 × 10 −3 ) (Supplementary Fig. 4 ).
CDK13 homology modeling.
To evaluate the impact of the identified DNM on the kinase domain of CDK13, we used the available experimentally determined crystal structure of CDK12, which shares over 91% amino acid sequence identity. We built the model of human CDK13 based on a structure of human CDK12 kinase domain (residues 714-1,063) in complex with cyclin-K (residues 1-267) with bound Mg-ADP and AlF 3 at 2.2 Å resolution (PDB 4NST) 16 using the SWISSMODEL server 39 (Supplementary Fig. 14) .
